MCRB

Seres Therapeutics, Inc.
CAPPED RATING

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics, Inc. (MCRB) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.7
EV / EBITDA -0.5
Rev Growth YoY 68.9%
Gross Margin 0.0%
Price Return 3M -68.9%
Price Return 12M -90.5%
Catalyst Signal 0.00
Market Cap $14.4M
TTM Revenue $2.1M
Price / Sales 6.8
ROE -144.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) C+ (2.7) D (1.5) F (0.6) C+ (2.6) C- (2.1)
2026-11-06 B- (3.0) F (0.4) C (2.2) D- (0.8) C+ (2.7) D+ (1.8)
2026-10-30 B- (3.0) F (0.4) C (2.2) D- (0.8) C+ (2.7) D+ (1.8)
2026-10-23 B- (3.0) F (0.4) C (2.2) D- (0.8) C+ (2.6) D+ (1.8)
2026-10-16 B- (2.9) F (0.4) C (2.2) D- (0.9) C+ (2.6) D+ (1.8)
Page 1 of 6